FindTrial
Sign In

Evaluation of dose responsiveness for T-705a in the treatment of seasonal infection with influenza

Evaluation of dose responsiveness for T-705a in the treatment of seasonal infection with influenza

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220495
Enrollment
Unknown
Registered
2008-01-08
Start date
2008-01-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza virus infection

Interventions

investigational material(s) Generic name etc : T-705a INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigational material : Oral

Sponsors

Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Male and female - Patients who show a positive reaction to influenza virus antigen using a test kit from nasal or pharyngeal swabs. - Patients with a temperature (axillary) of 38.0 degrees Celsius or more at the first visit - Patients with 2 or more of influenza-like symptoms

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The time to pyretolysis (Duration of fever)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026